Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Alpha Cognition Inc C.ACOG


Primary Symbol: ACOG

Alpha Cognition Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is engaged in developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company’s pipeline includes ALPHA-1062, ALPHA-0602, and ALPHA-0702 and ALPHA-0802 (GEMs). The Company’s ALPHA-1062 is a patented new chemical entity being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, with expected minimal gastrointestinal side effects. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI. ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein. It is in preclinical development for the treatment of ALS.


NDAQ:ACOG - Post by User

Post by stockpatrolon Apr 13, 2022 6:27pm
265 Views
Post# 34602088

You can check out $ACOG.v $ACOGF ’s pre-clinical data from A

You can check out $ACOG.v $ACOGF ’s pre-clinical data from A
You can check out $ACOG.v $ACOGF ’s pre-clinical data from ALPHA-1062 here 
 
https://twitter.com/alpha_cognition/status/1514292342857121796
 
The data is promising, FDA approval should be a strong catalyst for $ACOG.v 
 
Recently they Announced Change of CFO, Grant of Stock Options and Addition to the Board of Directors
<< Previous
Bullboard Posts
Next >>